Skip to main content
Top
Published in: Current Atherosclerosis Reports 1/2012

01-02-2012 | Nonstatin Drugs (W Borden, Section Editor)

Lipid Effects of Antihypertensive Medications

Authors: Roderick Deano, Matthew Sorrentino

Published in: Current Atherosclerosis Reports | Issue 1/2012

Login to get access

Abstract

Thiazide diuretics and beta-blockers are first-line therapies for hypertension unless there are compelling indications for other drug classes. Diuretics and beta-blockers, however, may worsen dyslipidemia and glucose tolerance whereas antihypertensive agents in other drug classes may have neutral or beneficial effects. Initial clinical trials of antihypertensive regimens suggested that blood pressure lowering was the most important aspect of therapy and that the adverse effects on lipids and glucose tolerance did not impact clinical outcomes. Newer trials, however, question this finding and implicate these pleotropic effects as contributing to the results of the trials. Patients with cardiometabolic risk factors may have compelling indications for agents that inhibit the renin-angiotensin-aldosterone system, relegating diuretics and beta-blockers to third-line therapy.
Literature
1.
go back to reference Chobanian AV, Bakris GL, Black HR, et al. The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA. 2003;289:2560–72.PubMedCrossRef Chobanian AV, Bakris GL, Black HR, et al. The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA. 2003;289:2560–72.PubMedCrossRef
2.
go back to reference Mokdad AH, Ford ES, Bowman BA, et al. Diabetes trends in the U.S.: 1990–1998. Diabetes Care. 2000;23:1278–83.PubMedCrossRef Mokdad AH, Ford ES, Bowman BA, et al. Diabetes trends in the U.S.: 1990–1998. Diabetes Care. 2000;23:1278–83.PubMedCrossRef
3.
go back to reference Gress TW, Nieto FJ, Shahar E, et al. Hypertension and anti-hypertensive therapy as risk factors for Type 2 diabetes mellitus. N Engl J Med. 2000;342:905–12.PubMedCrossRef Gress TW, Nieto FJ, Shahar E, et al. Hypertension and anti-hypertensive therapy as risk factors for Type 2 diabetes mellitus. N Engl J Med. 2000;342:905–12.PubMedCrossRef
4.
go back to reference Stas S, Appesh L, Sowers J. Metabolic safety of antihypertensive drugs: myth versus reality. Curr Hypertens Rep. 2006;8:403–8.PubMedCrossRef Stas S, Appesh L, Sowers J. Metabolic safety of antihypertensive drugs: myth versus reality. Curr Hypertens Rep. 2006;8:403–8.PubMedCrossRef
5.
go back to reference Weidmann P, de Courten M, Ferrari P, et al. Serum lipoproteins during treatment with antihypertensive drugs. J Cardiovasc Pharmacol. 1993;22 Suppl 6:S98–105.PubMed Weidmann P, de Courten M, Ferrari P, et al. Serum lipoproteins during treatment with antihypertensive drugs. J Cardiovasc Pharmacol. 1993;22 Suppl 6:S98–105.PubMed
6.
go back to reference Lardinois CK, Newman SL. The effects of antihypertensive agents on serum lipids and lipoproteins. Arch Intern Med. 1988;148:1280–8.PubMedCrossRef Lardinois CK, Newman SL. The effects of antihypertensive agents on serum lipids and lipoproteins. Arch Intern Med. 1988;148:1280–8.PubMedCrossRef
7.
go back to reference Lasser NL, Grandits G, Caggiula AQ, et al. Effects of antihypertensive therapy on plasma lipids and lipoproteins in the Multiple Risk Factor Intervention Trial. Am J Med. 1984;76:52–62.PubMedCrossRef Lasser NL, Grandits G, Caggiula AQ, et al. Effects of antihypertensive therapy on plasma lipids and lipoproteins in the Multiple Risk Factor Intervention Trial. Am J Med. 1984;76:52–62.PubMedCrossRef
8.
go back to reference Feher MD, Betteridge DJ. Lipids, lipoproteins, and coronary heart disease: implications for antihypertensive therapy. Cardiovasc Drugs Ther. 1989;3 Suppl 1:333–40.PubMedCrossRef Feher MD, Betteridge DJ. Lipids, lipoproteins, and coronary heart disease: implications for antihypertensive therapy. Cardiovasc Drugs Ther. 1989;3 Suppl 1:333–40.PubMedCrossRef
9.
go back to reference Kasiske BL, Ma JZ, Roberto SN, et al. Effects of antihypertensive therapy on serum lipids. Ann Intern Med. 1995;122:133–41.PubMed Kasiske BL, Ma JZ, Roberto SN, et al. Effects of antihypertensive therapy on serum lipids. Ann Intern Med. 1995;122:133–41.PubMed
10.
go back to reference Lakshman MR, Reda DJ, Matersib BJ, et al. Diuretics and beta-blockers do not have adverse effects at 1 year on plasma lipid and lipoprotein profiles in men with hypertension. Arch Intern Med. 1999;159:551–8.PubMedCrossRef Lakshman MR, Reda DJ, Matersib BJ, et al. Diuretics and beta-blockers do not have adverse effects at 1 year on plasma lipid and lipoprotein profiles in men with hypertension. Arch Intern Med. 1999;159:551–8.PubMedCrossRef
11.
go back to reference Weir MR, Moser M. Diuretics and beta-blockers: is there a risk for dyslipidemia? Am Heart J. 2000;139:174–83.PubMedCrossRef Weir MR, Moser M. Diuretics and beta-blockers: is there a risk for dyslipidemia? Am Heart J. 2000;139:174–83.PubMedCrossRef
12.
go back to reference ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic. JAMA. 2002;288:2981–97.CrossRef ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic. JAMA. 2002;288:2981–97.CrossRef
13.
go back to reference Stump CS, Hamilton MT, Sowers JR. Effect of anti-hypertensive agents on the development of type 2 diabetes mellitus. Mayo Clin Proc. 2006;81:796–806.PubMedCrossRef Stump CS, Hamilton MT, Sowers JR. Effect of anti-hypertensive agents on the development of type 2 diabetes mellitus. Mayo Clin Proc. 2006;81:796–806.PubMedCrossRef
14.
go back to reference Perez-Stable E, Caralis PV. Thiazide-induced disturbances in carbohydrate, lipid, and potassium metabolism. Am Heart J. 1983;106:245–51.PubMedCrossRef Perez-Stable E, Caralis PV. Thiazide-induced disturbances in carbohydrate, lipid, and potassium metabolism. Am Heart J. 1983;106:245–51.PubMedCrossRef
15.
go back to reference Lithell HO. Effect of antihypertensive drugs on insulin, glucose, and lipid metabolism. Diabetes Care. 1991;14:203–9.PubMedCrossRef Lithell HO. Effect of antihypertensive drugs on insulin, glucose, and lipid metabolism. Diabetes Care. 1991;14:203–9.PubMedCrossRef
16.
go back to reference Harper R, Ennis CN, Sheridan B, et al. Effects of low dose versus conventional dose thiazide diuretic on insulin action in essential hypertension. BMJ. 1994;309:226–30.PubMedCrossRef Harper R, Ennis CN, Sheridan B, et al. Effects of low dose versus conventional dose thiazide diuretic on insulin action in essential hypertension. BMJ. 1994;309:226–30.PubMedCrossRef
17.
go back to reference Sowers J, Bakris G. Antihypertensive therapy and the risk of Type 2 diabetes mellitus. New Engl J Med. 2000;342:969–70.PubMedCrossRef Sowers J, Bakris G. Antihypertensive therapy and the risk of Type 2 diabetes mellitus. New Engl J Med. 2000;342:969–70.PubMedCrossRef
18.
go back to reference Goldner MG, Zurkowitz H, Akgren S. Hyperglycemia and glycosuria due to thiazide derivatives administered in diabetes mellitus. New Engl J Med. 1960;262:405–505.CrossRef Goldner MG, Zurkowitz H, Akgren S. Hyperglycemia and glycosuria due to thiazide derivatives administered in diabetes mellitus. New Engl J Med. 1960;262:405–505.CrossRef
19.
go back to reference Shapiro AP, Benedek TG, Small JL. Effect of thiazides on carbohydrate metabolism in patients with hypertension. New Engl J Med. 1961;265:1028–33.CrossRef Shapiro AP, Benedek TG, Small JL. Effect of thiazides on carbohydrate metabolism in patients with hypertension. New Engl J Med. 1961;265:1028–33.CrossRef
20.
go back to reference Padwal R, Laupacis A. Antihypertensive therapy and incidence of type 2 diabetes. Diabetes Care. 2004;27:247–55.PubMedCrossRef Padwal R, Laupacis A. Antihypertensive therapy and incidence of type 2 diabetes. Diabetes Care. 2004;27:247–55.PubMedCrossRef
21.
go back to reference Elliott WJ, Meyer PM. Incident diabetes in clinical trials of antihypertensive drugs: a network meta analysis. Lancet. 2007;369:201–7.PubMedCrossRef Elliott WJ, Meyer PM. Incident diabetes in clinical trials of antihypertensive drugs: a network meta analysis. Lancet. 2007;369:201–7.PubMedCrossRef
22.
go back to reference SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension: final results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA. 1991;265:3255–64.CrossRef SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension: final results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA. 1991;265:3255–64.CrossRef
23.
go back to reference Papadopoulos DP, Papademetriou V. Metabolic side effects and cardiovascular events of diuretics: should a diuretic remain the first choice therapy in hypertension treatment? The case of yes. Clin Exp Hypertens. 2007;29:503–16.PubMedCrossRef Papadopoulos DP, Papademetriou V. Metabolic side effects and cardiovascular events of diuretics: should a diuretic remain the first choice therapy in hypertension treatment? The case of yes. Clin Exp Hypertens. 2007;29:503–16.PubMedCrossRef
24.
go back to reference Brook RD. Mechanism of differential effects of antihypertensive agents on serum lipids. Curr Hypertens Rep. 2000;2:370–7.PubMedCrossRef Brook RD. Mechanism of differential effects of antihypertensive agents on serum lipids. Curr Hypertens Rep. 2000;2:370–7.PubMedCrossRef
25.
go back to reference Weinberger MH. Mechanisms of diuretic effects on carbohydrate tolerance, insulin sensitivity and lipid levels. Eur Heart J. 1992;13(suppl G):5–9.PubMed Weinberger MH. Mechanisms of diuretic effects on carbohydrate tolerance, insulin sensitivity and lipid levels. Eur Heart J. 1992;13(suppl G):5–9.PubMed
26.
go back to reference Helderman JH, Elahi D, Andersen DK, et al. Prevention of the glucose intolerance of thiazide diuretics by maintenance of body potassium. Diabetes. 1983;32:106–11.PubMedCrossRef Helderman JH, Elahi D, Andersen DK, et al. Prevention of the glucose intolerance of thiazide diuretics by maintenance of body potassium. Diabetes. 1983;32:106–11.PubMedCrossRef
27.
go back to reference • Chatterjee R, Yeh HC, Shafi T, et al Serum and dietary potassium and risk of incident type 2 diabetes mellitus: the Atherosclerosis Risk in Communities (ARIC) study. Arch Intern Med. 2010;170:1745–51. This observational study suggests a link between serum potassium levels and the risk of incident diabetes mellitus and may help explain the higher incidence of diabetes in individuals treated with thiazide diuretics. PubMedCrossRef • Chatterjee R, Yeh HC, Shafi T, et al Serum and dietary potassium and risk of incident type 2 diabetes mellitus: the Atherosclerosis Risk in Communities (ARIC) study. Arch Intern Med. 2010;170:1745–51. This observational study suggests a link between serum potassium levels and the risk of incident diabetes mellitus and may help explain the higher incidence of diabetes in individuals treated with thiazide diuretics. PubMedCrossRef
28.
go back to reference Shafi T, Appel LJ, Miller ER, et al. Changes in serum potassium mediate thiazide-induced diabetes. Hypertension. 2008;52:1022–9.PubMedCrossRef Shafi T, Appel LJ, Miller ER, et al. Changes in serum potassium mediate thiazide-induced diabetes. Hypertension. 2008;52:1022–9.PubMedCrossRef
29.
go back to reference Menon DV, Arbique D, Wang Z, et al. Differential effects of chlorthalidone versus spironolactone on muscle sympathetic nerve activity in hypertensive patients. J Clin Endocrinol Metab. 2009;94:1361–6.PubMedCrossRef Menon DV, Arbique D, Wang Z, et al. Differential effects of chlorthalidone versus spironolactone on muscle sympathetic nerve activity in hypertensive patients. J Clin Endocrinol Metab. 2009;94:1361–6.PubMedCrossRef
30.
go back to reference Pepine C, Cooper-DeHoff R. Cardiovascular therapies and risk for development of diabetes. J Am Coll Cardiol. 2004;44:509–5012.PubMedCrossRef Pepine C, Cooper-DeHoff R. Cardiovascular therapies and risk for development of diabetes. J Am Coll Cardiol. 2004;44:509–5012.PubMedCrossRef
31.
go back to reference Hunninghake DB. Effects of celiprolol and other anti-hypertensive agents on serum lipids and lipoproteins. Am Heart J. 1991;121:696–701.PubMedCrossRef Hunninghake DB. Effects of celiprolol and other anti-hypertensive agents on serum lipids and lipoproteins. Am Heart J. 1991;121:696–701.PubMedCrossRef
32.
go back to reference Giugliano D, Acampora R, Marfella R, et al. Metabolic and cardiovascular effects of carvedilol and atenolol in non-insulin dependent diabetes mellitus and hypertension. Ann Intern Med. 1997;126:955–9.PubMed Giugliano D, Acampora R, Marfella R, et al. Metabolic and cardiovascular effects of carvedilol and atenolol in non-insulin dependent diabetes mellitus and hypertension. Ann Intern Med. 1997;126:955–9.PubMed
33.
34.
go back to reference Sharp R, Sirajuddin R, Sharief I. Impact of carvedilol on the serum lipid profile. Ann Pharmacother. 2008;42:564–71.PubMedCrossRef Sharp R, Sirajuddin R, Sharief I. Impact of carvedilol on the serum lipid profile. Ann Pharmacother. 2008;42:564–71.PubMedCrossRef
35.
go back to reference Bakris GL, Fonseca V, Katholi RE, et al. Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension. JAMA. 2004;292:2227–36.PubMedCrossRef Bakris GL, Fonseca V, Katholi RE, et al. Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension. JAMA. 2004;292:2227–36.PubMedCrossRef
36.
go back to reference Hedblad B, Wikstrand J, Janzon L, et al. Low dose metoprolol CR/XL and fluvastatin slow progression of carotid intima-media thickness: main results from the Beta-Blocker Cholesterol-Lowering Asymptomatic Plaque Study (BCAPS). Circ. 2001;103:1721–6. Hedblad B, Wikstrand J, Janzon L, et al. Low dose metoprolol CR/XL and fluvastatin slow progression of carotid intima-media thickness: main results from the Beta-Blocker Cholesterol-Lowering Asymptomatic Plaque Study (BCAPS). Circ. 2001;103:1721–6.
37.
go back to reference Wiklund O, Hulthe J, Wistrand J, et al. Effect of controlled release/extended release metoprolol on carotid intima-media thickness in patients with hypercholesterolemia: a 3-year randomized study. Stroke. 2002;33:572–7.PubMedCrossRef Wiklund O, Hulthe J, Wistrand J, et al. Effect of controlled release/extended release metoprolol on carotid intima-media thickness in patients with hypercholesterolemia: a 3-year randomized study. Stroke. 2002;33:572–7.PubMedCrossRef
38.
go back to reference Torp-Pedersen C, Metra M, Charlesworth A, et al. Effects of metoprolol and carvedilol on pre-existing and new onset diabetes in patients with chronic heart failure: data from the Carvedilol Or Metoprolol European Trial (COMET). Heart. 2007;93:968–73.PubMedCrossRef Torp-Pedersen C, Metra M, Charlesworth A, et al. Effects of metoprolol and carvedilol on pre-existing and new onset diabetes in patients with chronic heart failure: data from the Carvedilol Or Metoprolol European Trial (COMET). Heart. 2007;93:968–73.PubMedCrossRef
39.
go back to reference Pollare T, Lithell H, Selinus I, et al. Sensitivity to insulin during treatment with atenolol and metoprolol: a randomized, double blind study of effects on carbohydrate and lipoprotein metabolism in hypertensive patients. BMJ. 1989;298:1152–7.PubMedCrossRef Pollare T, Lithell H, Selinus I, et al. Sensitivity to insulin during treatment with atenolol and metoprolol: a randomized, double blind study of effects on carbohydrate and lipoprotein metabolism in hypertensive patients. BMJ. 1989;298:1152–7.PubMedCrossRef
40.
go back to reference Sarafidis PA, Bakris GL. Do the metabolic effects of beta blockers make them leading or supporting antihypertensive agents in the treatment of hypertension? J Clin Hypertens. 2006;8:351–6.CrossRef Sarafidis PA, Bakris GL. Do the metabolic effects of beta blockers make them leading or supporting antihypertensive agents in the treatment of hypertension? J Clin Hypertens. 2006;8:351–6.CrossRef
41.
go back to reference Rossner S, Taylor CL, Byington RP, et al. Long term propranolol treatment and changes in body weight after myocardial infarction. BMJ. 1990;300:902–3.PubMedCrossRef Rossner S, Taylor CL, Byington RP, et al. Long term propranolol treatment and changes in body weight after myocardial infarction. BMJ. 1990;300:902–3.PubMedCrossRef
42.
go back to reference Hara Y, Hamada M, Shigematsu Y, et al. Effect of beta blockers on insulin resistance in patients with dilated cardiomyopathy. Circ. 2003;67:701–4.CrossRef Hara Y, Hamada M, Shigematsu Y, et al. Effect of beta blockers on insulin resistance in patients with dilated cardiomyopathy. Circ. 2003;67:701–4.CrossRef
43.
go back to reference Malminiemi K. Long-term celiprolol therapy lowers fasting plasma leptin levels. Cardiovasc Drugs Ther. 2000;14:67–75.PubMedCrossRef Malminiemi K. Long-term celiprolol therapy lowers fasting plasma leptin levels. Cardiovasc Drugs Ther. 2000;14:67–75.PubMedCrossRef
44.
go back to reference Wikstrand J, Berglund G, Hedblad B, et al. Antiatherosclerotic effects of beta-blockers. Am J Cardiol. 2003;91:25H–9H.PubMedCrossRef Wikstrand J, Berglund G, Hedblad B, et al. Antiatherosclerotic effects of beta-blockers. Am J Cardiol. 2003;91:25H–9H.PubMedCrossRef
45.
go back to reference Wu J, Kraja AT, Oberman A, et al. A summary of the effects of antihypertensive medications on measured blood pressure. Am J Hypertens. 2005;18:935–42.PubMedCrossRef Wu J, Kraja AT, Oberman A, et al. A summary of the effects of antihypertensive medications on measured blood pressure. Am J Hypertens. 2005;18:935–42.PubMedCrossRef
46.
go back to reference Ferdinand K, Armani A. The management of hypertension in African Americans. Crit Pathw Cardiol. 2007;6:67–71.PubMedCrossRef Ferdinand K, Armani A. The management of hypertension in African Americans. Crit Pathw Cardiol. 2007;6:67–71.PubMedCrossRef
47.
go back to reference Sever P, Dahlof B, Poulter N, et al. Potential synergy between lipid-lowering and blood-pressure-lowering in the Anglo-Scandinavian Cardiac Outcomes Trial. Eur Heart J. 2006;27:2982–8.PubMedCrossRef Sever P, Dahlof B, Poulter N, et al. Potential synergy between lipid-lowering and blood-pressure-lowering in the Anglo-Scandinavian Cardiac Outcomes Trial. Eur Heart J. 2006;27:2982–8.PubMedCrossRef
48.
go back to reference Fogari R, Derosa G, Zoppi A, et al. Effect of delapril/manidipine vs olmesartan/hydrochlorothiazide combination on insulin sensitivity and fibrinogen in obese hypertensive patients. Intern Med. 2008;47:361–6.PubMedCrossRef Fogari R, Derosa G, Zoppi A, et al. Effect of delapril/manidipine vs olmesartan/hydrochlorothiazide combination on insulin sensitivity and fibrinogen in obese hypertensive patients. Intern Med. 2008;47:361–6.PubMedCrossRef
49.
go back to reference Mason RP. A rational for combined therapy with a calcium channel blocker and a statin: evaluation of basic and clinical evidence. Curr Drug Targets Cardiovasc Haematol Disord. 2005;5:489–501.PubMedCrossRef Mason RP. A rational for combined therapy with a calcium channel blocker and a statin: evaluation of basic and clinical evidence. Curr Drug Targets Cardiovasc Haematol Disord. 2005;5:489–501.PubMedCrossRef
50.
go back to reference Bellosta S, Bernin F. Lipophilic calcium antagonists in antiatherosclerotic therapy. Curr Atherosclerosis Rep. 2000;2:76–81.CrossRef Bellosta S, Bernin F. Lipophilic calcium antagonists in antiatherosclerotic therapy. Curr Atherosclerosis Rep. 2000;2:76–81.CrossRef
51.
go back to reference Nissen SE, Tuzcu EM, Libby P, et al. Effect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure. JAMA. 2004;292:2217–26.PubMedCrossRef Nissen SE, Tuzcu EM, Libby P, et al. Effect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure. JAMA. 2004;292:2217–26.PubMedCrossRef
52.
go back to reference Sarafidis P, McFarlane S. Antihypertensive agents, insulin sensitivity, and new-onset diabetes. Curr Diabetes Rep. 2007;7:191–9.CrossRef Sarafidis P, McFarlane S. Antihypertensive agents, insulin sensitivity, and new-onset diabetes. Curr Diabetes Rep. 2007;7:191–9.CrossRef
53.
go back to reference Pollare T, Lithell H, Berne C. A comparison of the effects of hydrochlorothiazide and captopril on glucose and lipid metabolism in patients with hypertension. N Engl J Med. 1989;321:868–73.PubMedCrossRef Pollare T, Lithell H, Berne C. A comparison of the effects of hydrochlorothiazide and captopril on glucose and lipid metabolism in patients with hypertension. N Engl J Med. 1989;321:868–73.PubMedCrossRef
54.
go back to reference The Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting-enzyme-inhibitor, ramipril, on cardiovascular events in high-risk individuals. N Engl J Med. 2000;342:145–53.CrossRef The Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting-enzyme-inhibitor, ramipril, on cardiovascular events in high-risk individuals. N Engl J Med. 2000;342:145–53.CrossRef
55.
go back to reference •• Vardeny O, Uno H, Braunwald E, et al. Opposing effects of beta blockers and angiotensin-converting enzyme inhibitors on development of new-onset diabetes mellitus in patients with stable coronary artery disease. Am J Cardiol. 2011;107:1705–09. These data from the PEACE trial show a nearly 9% increased risk of new-onset diabetes mellitus in CAD patients treated with beta-blockers. This risk was significantly attenuated if they were also treated with an ACE inhibitor. PubMedCrossRef •• Vardeny O, Uno H, Braunwald E, et al. Opposing effects of beta blockers and angiotensin-converting enzyme inhibitors on development of new-onset diabetes mellitus in patients with stable coronary artery disease. Am J Cardiol. 2011;107:1705–09. These data from the PEACE trial show a nearly 9% increased risk of new-onset diabetes mellitus in CAD patients treated with beta-blockers. This risk was significantly attenuated if they were also treated with an ACE inhibitor. PubMedCrossRef
56.
go back to reference Julius S, Kjedlsen SE. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomized trial. Lancet. 2004;363:2022–31.PubMedCrossRef Julius S, Kjedlsen SE. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomized trial. Lancet. 2004;363:2022–31.PubMedCrossRef
57.
go back to reference • Rizos C, Elisaf MS, Liberopoulos EN. Are the pleotropic effects of telmisartan clinically relevant? Curr Pharn Des. 2009;15:2815–32. The authors argue that the ARB telmisartan may have additional pleiotropic effects, especially in the realm of glucose metabolism, that make this agent potentially favorable over other agents. Clinical studies, however, have yet to show definitive results confirming superiority over other ARBs. CrossRef • Rizos C, Elisaf MS, Liberopoulos EN. Are the pleotropic effects of telmisartan clinically relevant? Curr Pharn Des. 2009;15:2815–32. The authors argue that the ARB telmisartan may have additional pleiotropic effects, especially in the realm of glucose metabolism, that make this agent potentially favorable over other agents. Clinical studies, however, have yet to show definitive results confirming superiority over other ARBs. CrossRef
58.
go back to reference Holzgreve H, Nakov R. Antihypertensive therapy with verapamil SR plus trandolapril versus atenolol plus chlorthalidone on glycemic control. Am J Hypertens. 2003;16:381–6.PubMedCrossRef Holzgreve H, Nakov R. Antihypertensive therapy with verapamil SR plus trandolapril versus atenolol plus chlorthalidone on glycemic control. Am J Hypertens. 2003;16:381–6.PubMedCrossRef
59.
go back to reference Jamerson K, Weber MA, Bakris GL, et al. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. New Engl J Med. 2008;359:2417–28.PubMedCrossRef Jamerson K, Weber MA, Bakris GL, et al. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. New Engl J Med. 2008;359:2417–28.PubMedCrossRef
60.
go back to reference Scheen A. Renin-angiotensin system inhibition prevents type 2 diabetes mellitus. Part 2: overview of physiological and biochemical mechanisms. Diabetes Met. 2004;30:498–505.CrossRef Scheen A. Renin-angiotensin system inhibition prevents type 2 diabetes mellitus. Part 2: overview of physiological and biochemical mechanisms. Diabetes Met. 2004;30:498–505.CrossRef
61.
go back to reference McFarlane SI, Kumar A, Sowers JR. Mechanism by which angiotensin-converting enzyme inhibitors prevent diabetes and cardiovascular disease. Am J Cardiol. 2003;91:30H–7H.PubMedCrossRef McFarlane SI, Kumar A, Sowers JR. Mechanism by which angiotensin-converting enzyme inhibitors prevent diabetes and cardiovascular disease. Am J Cardiol. 2003;91:30H–7H.PubMedCrossRef
62.
63.
go back to reference Mason RP. A rational for combination therapy in risk factor management: a mechanistic perspective. Am J Med. 2005;118(Suppl 12A):54–61.PubMedCrossRef Mason RP. A rational for combination therapy in risk factor management: a mechanistic perspective. Am J Med. 2005;118(Suppl 12A):54–61.PubMedCrossRef
64.
go back to reference Luscher TF, Wenzel RR, Moreau P, et al. Vascular protective effects of ACE inhibitors and calcium antagonists: theoretical basis for a combination therapy in hypertension and other cardiovascular diseases. Cardioavsc Drugs Ther. 1995;9 Suppl 3:509–23.CrossRef Luscher TF, Wenzel RR, Moreau P, et al. Vascular protective effects of ACE inhibitors and calcium antagonists: theoretical basis for a combination therapy in hypertension and other cardiovascular diseases. Cardioavsc Drugs Ther. 1995;9 Suppl 3:509–23.CrossRef
65.
go back to reference Pollare T, Lithell H. Application of prazosin is associated with an increase of insulin sensitivity in obese patients with hypertension. J Hypertens. 1988;31:415–20. Pollare T, Lithell H. Application of prazosin is associated with an increase of insulin sensitivity in obese patients with hypertension. J Hypertens. 1988;31:415–20.
66.
go back to reference • Chapman N, Chen CY, Fukita T, et al. Time to re-appraise the role of alpha- adrenoceptor antagonists in the management of hypertension. J Hypertens. 2010;28:1796–803. Data from the ASCOT trial show that the addition of a long-acting preparation of the alpha-blocker doxazosin brought about a further blood pressure lowering and a modest reduction in lipids without an increase in heart failure. The authors suggest that alpha-blockers are safe as add-on antihypertensive therapy. PubMedCrossRef • Chapman N, Chen CY, Fukita T, et al. Time to re-appraise the role of alpha- adrenoceptor antagonists in the management of hypertension. J Hypertens. 2010;28:1796–803. Data from the ASCOT trial show that the addition of a long-acting preparation of the alpha-blocker doxazosin brought about a further blood pressure lowering and a modest reduction in lipids without an increase in heart failure. The authors suggest that alpha-blockers are safe as add-on antihypertensive therapy. PubMedCrossRef
Metadata
Title
Lipid Effects of Antihypertensive Medications
Authors
Roderick Deano
Matthew Sorrentino
Publication date
01-02-2012
Publisher
Current Science Inc.
Published in
Current Atherosclerosis Reports / Issue 1/2012
Print ISSN: 1523-3804
Electronic ISSN: 1534-6242
DOI
https://doi.org/10.1007/s11883-011-0214-z

Other articles of this Issue 1/2012

Current Atherosclerosis Reports 1/2012 Go to the issue

Nonstatin Drugs (W Borden, Section Editor)

Novel Antiplatelet Therapies

Statin Drugs (M Clearfield, Section Editor)

Initiation of Statin Therapy: Are There Age Limits?